Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Expression of DLK1 Gene in the Bone Marrow Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significance.

    ... positive correlation with the proportion of bone marrow blasts (r=0.467, P<0.05). Moreover, DLK1 mRNA expression was significantly ... positively correlated with the proportion of the bone marrow blasts. A high expression of DLK1 gene suggested a higher malignant clone ...

    Research Article last updated 06/20/2013 - 10:42am.

  2. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... include analysis of peripheral cytopenias, percentage of blasts in the bone marrow and cytogenetic characteristics. The most ... based on risk, transfusion needs, percent of bone marrow blasts, and, more recently, cytogenetic profile. Goals of therapy are different ...

    Research Article last updated 07/31/2012 - 2:02pm.

  3. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... include analysis of peripheral cytopenias, percentage of blasts in the bone marrow, and cytogenetic characteristics. The most ... based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic profile. Goals of therapy are different in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Clinical effect of point mutations in myelodysplastic syndromes

    ... including specific cytopenias, the proportion of blasts , and overall survival. RESULTS: We identified somatic ... all comparisons) and an increased proportion of bone marrow blasts (P<0.006 for all comparisons). In a multivariable Cox regression model, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.

    ... to pre-defined criteria ( cellularity <20% and blasts <10%). Marrow cellularity (P<0.0001) and blast% (P=0.03) were ... with inferior OS after HCT (HR=1.22 for each 10% marrow blasts, 95% CI: 1.02-1.46). For AML/MDS patients, there was a suggestion that ...

    Research Article last updated 06/28/2013 - 1:30pm.

  6. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... remissions, and reduction in bone marrow blasts . 5-azacitidine has also been shown to improve overall survival. ...

    Research Article last updated 05/26/2015 - 12:13pm.

  7. Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival

    ... 125 cytopenic patients: 40 lower grade MDS (<5% marrow blasts ), 24 higher grade MDS, and 61 benign. RESULTS: CD271+ MSC ...

    Research Article last updated 11/25/2014 - 8:57am.

  8. Clinical and genetic predictors of prognosis in myelodysplastic syndromes

    ... blood cytopenias, the proportion of bone marrow blasts , and specific karyotype abnormalities. Other factors including age, ...

    Research Article last updated 06/19/2014 - 1:30pm.

  9. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... acute myeloid leukaemia (<30% bone marrow blasts , n = 102), there was a statistically significant reduction in ...

    Research Article last updated 08/04/2014 - 8:37am.

  10. Myelodysplastic syndromes

    ... marrow with dysplasia, with or without excess of blasts . Prognosis depends largely on the marrow blast percentage, number ...

    Research Article last updated 04/16/2014 - 12:04pm.